Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImmunAID

Financiado

Cerrado

Immunome project consortium for AutoInflammatory Disorders

Systemic autoinflammatory diseases (SAID) encompass several rare disorders characterised by extensive clinical and biological inflammation. SAID are caused by the dysregulation of the innate immune system. Due to numerous and unsp... ver más

31/10/2024

INSERM

16M€

Presupuesto del proyecto: 16M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 26 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-10-31

SC1-PM-03-2017: Diagnostic characterisation of rare...

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

26 Participantes

INSERM

3.06M€ | Lider

UOI RESEARCHCOMMITTEE

369.69K€ | Participante

ERASMUS MC

2.56M€ | Participante

UKCL

12.79K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AIPM Analysis of protein misfolding as a pathogenetic mechanism i... 100K€ Cerrado

PID2020-119032RB-I00 MEDICINA DE PRECISION EN ENFERMEDADES AUTOINMUNES: INTEGRACI... 145K€ Cerrado

PRECISESADS Molecular Reclassification to Find Clinically Useful Biomark... 23M€ Cerrado

PID2021-125106OB-C31 VARIANTES POST-CIGOTICAS RESPONSABLES DE MOSAICISMO GENETICO... 218K€ Cerrado

ALLFUN Fungi in the setting of inflammation allergy and autoimmune... 7M€ Cerrado

ARCAID Amsterdam Rheumatology Center for AutoImmune Diseases 4M€ Cerrado

Duración del proyecto: 78 meses Fecha Inicio: 2018-04-27
Fecha Fin: 2024-10-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 16M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Systemic autoinflammatory diseases (SAID) encompass several rare disorders characterised by extensive clinical and biological inflammation. SAID are caused by the dysregulation of the innate immune system. Due to numerous and unspecific symptoms, tentative diagnosis often leads to failure/delay and inadequate treatments. ImmunAID will deliver a method for rapid and accurate diagnosis across all the spectrum of SAID, in order to improve clinical management of SAID patients. Thanks to parallel analyses run on samples from more than 600 patients with monogenic or undiagnosed SAID collected throughout Europe, Immunaid will generate a unique and comprehensive set of data, based on unbiased multiomics approaches (gene, transcript, protein, microbiome), and hypothesis-driven assays exploring inflammasome, inflammation resolution and immune networks. A centralised data management strategy will enable to conduct integrated analyses for diagnostic biomarker identification. In a discovery phase, semi-supervised clustering of omics data will be combined to supervised analysis of pathway-related data to provide robust classification and strong link to clinical features/impact. The related biomarkers will further be validated externally on independent samples and cohorts. Overall, ImmunAID will disentangle the spectrum of SAID, and propose a new omics- and pathogenesis-based SAID classification associated to a clinical decision making algorithm implementable in daily practice. An efficient dissemination plan will target e.g. guideline-forming bodies, the medical community and patients with the help of the ERN RITA and with the objective of turning our results into clinical practice. To further support this, proactive innovation management will be implemented. To reach its ambitious goals, ImmunAID interdisciplinary consortium gathers high-level partners, including the founder of SAID concept, experts in omics science, immunology, bioinformatics, and involves clinicians and patient advocacy groups.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores